Research Article

Yu Miao, Jiawei Lu, Junhui Yin, Changchun Zhou, Yaping Guo*, and Shumin Zhou*

Yb$^{3+}$-containing chitosan hydrogels induce B-16 melanoma cell anoikis via a Fak-dependent pathway

https://doi.org/10.1515/ntrev-2019-0056
Received Feb 28, 2019; accepted Jul 10, 2019

Abstract: Melanoma is the most lethal dermal tumor, and a high recurrence rate and skin defects are two main serious problems. An antimelanoma material, which effectively inhibits tumor recurrence and possesses excellent biocompatibility, is urgently needed to treat melanoma. In this study, we developed a novel antitumor Yb$^{3+}$ [Yb(NO$_3$)$_3$]$_2$-containing chitosan hydrogel (Yb-CS hydrogel) by dissolving Yb(NO$_3$)$_3$ and chitosan in acetic acid solution and forming composite hydrogels by a freeze-drying process after adding NaOH to the mixed solution. In vitro studies demonstrated that the Yb$^{3+}$ produces effect of inducing cell death in Yb-CS hydrogel. Moreover, we found that the Yb-CS hydrogel inhibited a focal adhesion kinase (FAK)-dependent signaling pathway and induced B-16 cell anoikis. However, the Yb-CS hydrogel was less effective on L929 normal mouse dermal cells. In vivo studies showed that the Yb-CS hydrogel inhibited the recurrence of melanoma in a mouse bare xenograft tumor model. We concluded that the Yb-CS hydrogel could potentially be used in the antimelanoma field, especially in the inhibition of melanoma recurrence.

Keywords: Yb-CS hydrogel; Yb$^{3+}$; anoikis

Abbreviations

Yb-CS Hydrogel [Yb(NO$_3$)$_3$]$_2$-containing chitosan hydrogel
FAK focal adhesion kinase
RTCA real-time cell analyzer
XRD X-ray powder diffraction
TG-DTA thermogravimetric analysis

1 Introduction

Melanoma, which is responsible for over 75% of skin cancer-related deaths and threatens the lives of approximately 50,000 patients each year [1], has the highest morbidity among lethal dermal neoplasms. Melanoma morbidity has increased by 199% from 1975 to 2010 according to the Surveillance, Epidemiology, and End Results (SEER) database [2]. More than 95% of melanoma tumors occur in the skin, with a high malignance and high potential for metastasis [3]. Currently, the main treatments for melanoma include surgical resection, chemotherapies, radiotherapies, targeted therapies and immunotherapies [4]. However, the high recurrence rate (up to 30% for localized melanoma and 60% for regional nodal disease) [5] and skin defects after surgery remain the two main serious problems suffered by melanoma patients [6, 7]. In fact, there is still no international consensus on a standard adjuvant therapy for preventing recurrence in patients because of the serious side effects of adjuvant therapy, [1] low sensitivity to chemotherapy or radiotherapy [8] and drug resistance [9]. Therefore, the development of an effective adju-

Junhui Yin: Institution of microsurgery for Limbs, Department of Orthopedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China

Changchun Zhou: National Engineering Research Center for Biomaterials, Sichuan University, Chengdu 610064, China

Yu Miao and Jiawei Lu contributed equally to this work

*Corresponding Author: Yaping Guo: The Education Ministry Key Lab of Resource Chemistry and Shanghai Key Laboratory of Rare Earth Functional Materials, Shanghai Normal University, Shanghai 200234, China; Email: ypguo@shnu.edu.cn. Tel: +86 13651875400

*Corresponding Author: Shumin Zhou: Institution of microsurgery for Limbs, Department of Orthopedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China; Email: zhoushumin_zw@126.com; Tel: +86 18502127296

Yu Miao: Department of Orthopedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China

Jiawei Lu: The Education Ministry Key Lab of Resource Chemistry and Shanghai Key Laboratory of Rare Earth Functional Materials, Shanghai Normal University, Shanghai 200234, China

Yu Miao and Jiawei Lu contributed equally to this work

Open Access. © 2019 Y. Miao et al., published by De Gruyter. This work is licensed under the Creative Commons Attribution 4.0 License
vant treatment to inhibit the relapse of melanoma remains urgently needed in the clinic worldwide.

Lanthanides have been widely studied as antitumor chemotherapeutic reagents in various types of malignant tumors, e.g., lanthanum (La) in cervical cancer, [10] ovarian cancer [11] and gastric cancer [12]; gadolinium (Gd) in osteosarcoma, [13] prostate cancer [14] and liver cancer [15]; and cerium (Ce) in breast cancer [16]. However, for decades, ytterbium (Yb), which also belongs to the lanthanide series, has been mainly used as a radioembolization element rather than a chemotherapeutic reagent for treating tumors [17, 18]. Therefore, we hypothesized that yttrium also has the capability of inhibiting tumor cell growth. As reported in many previous studies, lanthanides show anticancer effects by suppressing cell proliferation and inducing cell apoptosis at higher concentrations, but lanthanides promote cell growth at low concentrations [19]. Therefore, maintaining suitable concentrations of Yb$^{3+}$ ions is the key to achieving therapeutic effects.

In present study, an Yb$^{3+}$-containing chitosan hydrogel (Yb-CS hydrogel) that selectively induced anoikis (a special type of programmed cell death) in B-16 mouse melanoma cells with less effects on L929 normal skin dermal cells is developed. Moreover, the Yb-CS hydrogel had no harmful influence on skin union and did not cause peripheral normal tissue damage. Therefore, the development of the Yb-CS hydrogel not only provides a new material for accompanying therapeutic strategies for melanoma but also facilitates the application of yttrium for tumor treatment.

2 Materials and methods

2.1 Preparation of the Yb$^{3+}$-containing chitosan hydrogel

Yb$^{3+}$ solutions (10$^{-2}$ M) were prepared by dissolving Yb(NO$_3$)$_3$·5H$_2$O (Aladdin, Shanghai, China) in 2.0 wt% acetic acid solution. Chitosan (CS) powder (0.5 g) was dissolved in the Yb$^{3+}$ solution (20 ml) under magnetic stirring. After stirring for 2 h, the mixed solutions (0.5 ml) were transferred to molds in 24-well plates. The samples were treated with 5.0 wt% sodium hydroxide solutions at 37°C for 3 h and then washed with 10$^{-2}$ M Yb(NO$_3$)$_3$ solution up to pH=7.0. The products (Yb$^{3+}$-containing CS hydrogels) are abbreviated as Yb-CS hydrogels. In addition, CS hydrogels without Yb$^{3+}$ ions were developed under the same conditions as a negative control.

2.2 The release of Yb$^{3+}$ from Yb-CS hydrogels

The release experiment was carried out in an 80 rpm oscillator at 37°C. Three slices of Yb-CS hydrogels were immersed in 5 ml deionized water. At predetermined time-points (3, 6, 12, 24, 48, 72, 96 and 120 h), 1.0 ml of release medium was removed to determine the concentrations of Yb$^{3+}$ ions and was replaced with the same volume of deionized water. The Yb$^{3+}$ concentrations were determined by inductively coupled plasma/optical emission spectrometry (ICP/OES; Perkin Elmer, OPTIMA 3300 DV).

2.3 Characterization

Water in the Yb-CS and CS hydrogels was removed by a freeze-drying method to characterize their morphology, phase and thermal performance. For biological tests, the hydrogels were not freeze-dried. Scanning electron microscopy (SEM; JEOL, JSM-6380LV) and energy-dispersive spectrometry (EDS) were used to characterize the morphology and element distribution of the samples. The phases of the Yb-CS and CS hydrogels were determined by X-ray powder diffraction (XRD; D/max-III C). The functional groups of the samples were characterized in a wavenumber range of 4000-400 cm$^{-1}$ at a resolution of 2 cm$^{-1}$ by Fourier transform infrared spectroscopy (FTIR; Nicolet 5DX). The thermal performances of the samples were detected by thermogravimetric analysis (TG-DTA, Perkin-Elmer).

2.4 Cell culture

Cell lines (B-16 mouse melanoma cells and L929 mouse skin fibroblast cells) were purchased from CCTCC (China Centre for Type Culture Collection). Both cell lines were cultured in DMEM (GIBCO, USA) supplemented with 10% FBS (GIBCO, USA) and 1% penicillin/streptomycin. The cells were grown in a humidified atmosphere with 5% CO$_2$ at 37°C.

2.5 Cell proliferation assays

A Cell Counting Kit-8 assay (CCK-8, Beyotime, China) was used to detect cell viability. Cells were seeded in 96-well plates at a density of 3000 cells/well and treated with CS hydrogels and Yb-CS hydrogels with Yb$^{3+}$ concentrations of 0.1 and 1.0 mmol/L after cell adhesion. Then, the absorbance was measured at a wavelength of 450 nm for 5
days using a Bio-Tek microplate reader ELX800 (Bio Tek, USA).

For real-time cell analysis, B-16 and L929 cells were seeded at a density of 5×10^4 cells/well into an E-plate 16 (ACEA Biosciences, CA, USA), respectively. Then, the cells were treated with Yb^{3+} at concentrations of 0, 0.01, 0.1, 0.5, 1.0, and 1.5 mmol/L in a total 200 µL medium and monitored on the xCELLigence Real-Time Cell Analyzer Dual Plate (RTCA DP) instrument (ACEA Biosciences, USA). The detection interval was 1 h, and the total detection duration was 120 h. Data were collected using RTCA software (Version 2.0; ACEA Biosciences Inc., San Diego, CA, USA).

2.6 Cell apoptosis analysis

For on-gel apoptosis assays, B-16 and L929 cells were seeded in 96-well plates at a density of 1×10^4 cells/well and covered with CS hydrogels and Yb-CS hydrogels containing Yb^{3+} at concentrations of 0.1, 1.0, and 1.5 mmol/L. Approximately 24 h later, the cells were washed with 1× phosphate-buffered saline (PBS) and stained with annexin V and propidium iodide (PI) (Dojindo Laboratories, Japan) for approximately 20 min. Images were acquired using a Leica Dmi6000B microscope.

For FCM-based apoptosis assays, cells were seeded in 6-well plates at a density of 3×10^5 cells/well and treated with Yb^{3+} at concentrations of 0, 0.01, 0.1, 1.0, and 1.5 mmol/L after 24 h. Then, the cells were collected and washed with PBS followed by staining with annexin V and PI (Dojindo Laboratories, Japan) for approximately 20 min. The apoptosis rates of these cells were analyzed by a FACSCalibur BD flow cytometer.

2.7 Cell adhesion assay

For on-gel adhesion assays, B-16 and L929 cells were seeded at a density of 1×10^5 cells/well in 96-well plates filled with hydrogels containing Yb^{3+} at concentrations of 0, 0.01, 0.1, 0.5, 1.0, and 1.5 mmol/L after 24 h. Then, the cells were washed with PBS 3 times and stained with SYBR Green I for 20 min, followed by analysis under a Leica Dmi6000B microscope.

For real-time cell analysis, B-16 and L929 cells were seeded at a density of 5×10^3 cells/well into an E-plate 16 (ACEA Biosciences, San Diego, CA). Then, the cells were treated with Yb^{3+} at concentrations of 0, 0.01, 0.1, 0.5, 1.0, and 1.5 mmol/L in a total of 200 µL medium and monitored on an xCELLigence Real-Time Cell Analyzer Dual Plate (RTCA DP) instrument (ACEA Biosciences, USA). The detection interval was 1 min, and the total detection duration was 6 h. Data were collected using RTCA software (Version 2.0; ACEA Biosciences Inc., San Diego, CA, USA).

2.8 Cytoskeletal staining

To detect morphological changes related to anoikis of B-16 and L929 cells treated with Yb^{3+} at different concentrations, cytoskeletal staining was carried out. B-16 and L929 cells were seeded in 96-well plates at a density of 1×10^4 cells/well and treated with Yb^{3+} at concentrations of 0, 0.01, 0.1, 0.5, 1.0, and 1.5 mmol/L after cell adhesion. Twenty-four hours later, the cells were fixed with 4% paraformaldehyde for 30 min at room temperature (RT), washed 3 times with PBS, and permeabilized with 0.1% Triton X-100 (Sigma-Aldrich, MO, USA) for 5 min. After washing with PBS, the cells were incubated with fluorescent phalloidin (1:50 dilution) for 30 min according to the manufacturer’s directions. Images were analyzed and acquired by a DM6000B Leica fluorescence microscope.

2.9 Western blotting

Cells were seeded in 6-well plates at a density of 3×10^5 cells/well and treated with CS hydrogels, Yb-CS hydrogels and Yb^{3+} at concentrations of 0, 0.01, 0.1, 0.5, 1.0, and 1.5 mmol/L after cell adhesion. Approximately 24 h later, the cells were collected and lysed using RIPA Lysis Buffer (Santa Cruz, TX, USA). Western blotting was performed as previously described [20]. Primary antibodies specific to PARP, caspase-3, caspase-9, Fak, P-Fak, Akt, P-Akt (1:1,000 dilution; Cell Signaling Technology, USA) and β-actin (1:5,000 dilution; Cell Signaling Technology, USA) were used. The blots were then incubated with goat anti-rabbit or anti-mouse secondary antibodies (1:3,000 dilution; Cell Signaling Technology, USA) and visualized using enhanced chemiluminescence.

2.10 Mouse experiment

Approximately 5×10^5 B-16 melanoma cells were injected into both sides of the abdomen in subcutaneous tissues of Sprague-Dawley (SD) mice. After 10 days of tumor cell inoculation, both sides of the tumor were partially resected (approximately 5 mm^3 of tumor tissue remained). Then, we covered the wound with an Yb-CS hydrogel on the left side and a blank hydrogel on the right side. Then, the wound was sutured, and the remaining open area was covered.
with gauze and a plastic protector to prevent the mice from biting each other. Recurrence of melanoma was analyzed at 2 weeks after resection.

2.11 Immunohistochemistry (IHC) staining

IHC staining was carried out as described previously [21]. Briefly, hematoxylin and eosin (HE) staining was performed to analyze the histological features and structures of skin and melanoma. IHC staining of the ki-67 antigen was employed to analyze cell proliferation. Images were acquired using a DM4000B Leica microscope.

2.12 Statistical analysis

Statistical analysis was performed with SPSS (version 17.0) and GraphPad Prism 6.0 software. Data were analyzed using two-tailed Student’s t-test for comparisons between two groups. For experiments involving more than two groups, ANOVA followed by Bonferroni’s multiple comparisons test was employed. P<0.05 was considered statistically significant and labeled as “*”, and p<0.01 was considered statistically significant and labeled as “**”.

3 Results

3.1 Morphology of Yb-CS hydrogels

The Yb-CS hydrogels were fabricated by the following steps: (i) CS and Yb(NO$_3$)$_3$ were dissolved in acetic acid solution; and (ii) the mixed solution was treated with NaOH solution, resulting in the formation of composite hydrogels, as shown in Figure 1. SEM imaging revealed that the Yb-CS hydrogels exhibited rough surfaces (Figure 1a), which originated from the evaporation of water during the freeze-drying process. The Yb-CS hydrogels mainly in-
Yb\(^{3+}\)-containing chitosan hydrogels induce B-16 melanoma cell anoikis via a Fak-dependent pathway

3.2 Structure and thermal property of Yb-CS hydrogels

The phase structures and functional groups of the Yb-CS hydrogels were characterized by XRD and FTIR, and the blank CS hydrogels were used as the control group (Figure 2a and 2b). The XRD patterns indicated that both the blank CS hydrogels and Yb-CS hydrogels exhibited amorphous phases, as confirmed by the halo peaks at approximately 20–30° (Figure 2a). Moreover, peaks attributed to Yb-containing compounds were not detected in the XRD pattern, suggesting that the Yb element existed as Yb\(^{3+}\) ions in the hydrogels.

Functional groups of the control CS hydrogels and Yb-CS hydrogels were detected by FTIR. For both samples, characteristic bands attributed to CS were detected (Figure 2b). The broad peak at approximately 3434 cm\(^{-1}\) was ascribed to the stretching vibration of the –OH and/or –NH\(_2\) groups [22]. The band at 1597 cm\(^{-1}\) corresponded to the N–H deformation vibration of the amino group, and the band at 890 cm\(^{-1}\) corresponded to the N–H wagging vibration [23]. The characteristic bands attributed to C–N in the primary and secondary amide groups were located at 1384 and 1319/1257 cm\(^{-1}\), respectively [22]. The bands at 1090 and 1155 cm\(^{-1}\) were ascribed to the C–O stretching vibration and bridge oxygen stretching vibration, respectively [24]. Characteristic bands attributed to NO\(^{-3}\) ions were detected in the Yb-CS hydrogels but not in the blank CS hydrogels. The bands at 1762 and 825 cm\(^{-1}\) were attributed to stretching modes of NO\(^{-3}\) ions. The peak at 1383 cm\(^{-1}\) became strong, which was attributed to the
After the freeze-drying process, the thermal behaviors of the CS and Yb-CS hydrogels were detected by TG-DTA (Figures 2c and 2d). For the control CS hydrogels, a weight loss of approximately 15.0% at approximately 50-100°C was attributed to the loss of adsorbed water. The corresponding endothermic peak was observed at approximately 68°C. In the temperature range of 100-550°C, a weight loss of approximately 85% was detected, as shown in Figure 2c. Two exothermic peaks at approximately 307 and 440°C were ascribed to depolymerization of acetylated/deacetylated units of the CS chain and the decomposition of CS, respectively. The TG-DTA curves of the Yb-CS hydrogels were similar to those of the pure CS hydrogels (Figure 2c and 2d). Notably, a strong exothermic peak was observed at approximately 507°C, which was attributed to the decomposition of NO₃⁻ ions in the hydrogels.

### 3.3 Yb³⁺ ions release property of Yb-CS hydrogels

The in vitro release performance of Yb³⁺ ions was analyzed after the Yb-CS hydrogels were immersed in deionized water. The concentrations of Yb³⁺ ions were determined by ICP/OES at different timepoints (Figure 3a and 3b). The release rate of Yb³⁺ ions was mainly correlated to the concentration gradient between the release medium and the hydrogels. In the first stage (within 24 h after immersion), Yb³⁺ ions were quickly released from the Yb-CS hydrogels because of the high concentration gradient. With increasing concentrations of Yb³⁺ ions in the medium, the Yb³⁺ release rate decreased gradually to a dynamic equilibrium. After 5 days, the cumulative release concentration and cumulative release ratio were 1.30 mM and 43.3%, respectively.

### 3.4 The Yb-CS hydrogel induces the apoptosis of B-16 and L929 cells

To analyze whether the Yb³⁺-containing hydrogel inhibits the progression of melanoma cells in the skin microenvironment, the B-16 mouse melanoma cell line and the L929 dermal fibroblast cell line were cultured and treated with no hydrogels (control), blank hydrogels and hydrogels containing Yb³⁺ at different concentrations (0.1 and 1 mM). Cell viability was detected by a CCK-8 assay kit. The results showed that there was no difference between the control group and the blank CS hydrogel group; however, the fold change significantly decreased (P<0.01) for cells treated with CS hydrogels containing high concentrations of Yb³⁺ compared with those in the control group and blank CS hydrogel group (Figure 4a). To verify whether this decrease in cell viability was attributed to cell apoptosis, we determined the apoptosis rates of B-16 and L929 cells on the hydrogels using an annexin V and PI staining kit and analyzed the staining by fluorescence microscopy. A typical early apoptotic phenomenon was observed in the Yb-CS hydrogel-treated B-16 cells with increasing Yb³⁺ concentrations because the number of annexin V-positive cells increased with increasing Yb³⁺ concentrations (Figure 4b). Then, we detected typical apoptosis proteins, PARP and cleaved-PARP. The results showed that the expression level of cleaved-PARP (the active form of PARP) greatly increased in the Yb-CS hydrogel (1.0 mM)-treated group, while the expression level of PARP (the inactive form of PARP) decreased in the Yb-CS hydrogel group compared with that in the control and blank CS hydrogel.
Yb$^{3+}$-containing chitosan hydrogels induce B-16 melanoma cell anoikis via a Fak-dependent pathway.

Figure 4: Yb$^{3+}$ is the main factor that induces apoptosis in the Yb-CS hydrogel. (a) The absorption values of B-16 and L929 cells decreased in the Yb-CS hydrogel group. (b) Annexin V (green) and PI (red) double staining of B-16 and L929 cells on hydrogels containing Yb$^{3+}$ at different concentrations. (c) Western blot of apoptosis marker proteins (PARP and its cleaved form) in B-16 and L929 cells treated with no hydrogels (control), blank CS hydrogels and Yb-CS hydrogels. *p < 0.05, **p < 0.01
3.5 The Yb-CS hydrogel inhibits melanoma relapse in mouse models

To analyze the in vivo effect of Yb$^{3+}$-containing hydrogels on melanoma, a C57 melanoma mouse model was employed. The procedure of the mouse experiment is described in Figure 5a. Briefly, xenografts on both sides of tumor-bare mice were partially resected (approximately 5 mm$^3$ of the tumor remained) at 10 days after tumor formation. The tumor remnants were used to determine whether the Yb-CS hydrogel (1.0 mM) inhibits the recurrence of melanoma. Then, we covered the wound with a hydrogel containing Yb$^{3+}$ on the left side and a blank hydrogel on the other side (Figure 5b-5e). After 2 weeks, the abdomen side covered with the Yb$^{3+}$-containing hydrogel was cured with only one exception (1 out of 5 mice) (Figure 5f), while only some gel remnants were observed under the epidermal side of the mice (Figure 5k-5m), whereas melanoma tissue was observed under the epidermal tissue from the control side of the mice (Figure 5g). To confirm the recurrence of melanoma, HE staining and IHC of ki-67 of skin tissues from both sides of the mice with xenografts were performed. Obvious melanoma tissue was observed under the epidermal tissue from the control side of the mice (Figure 5k-5m), whereas only some gel remnants were observed under the epidermal tissue from the Yb$^{3+}$-containing gel-covered side of the mice (Figure 5h-5j). In addition, ki-67 staining of the neoplasm under the epidermal tissue from the control side of the mice was deeply stained, which verified that these tissues were indeed tumor tissues (Figure 5m). Therefore, all the results mentioned above demonstrated that the Yb-CS hydrogel inhibits the recurrence of melanoma in a mouse model.

3.6 Yb$^{3+}$ induces higher apoptosis rates in B-16 cells than in L929 cells

Because the concentration of Yb$^{3+}$ in the hydrogel was imprecise and the Yb$^{3+}$ ion was shown to primarily induce apoptosis, we used the Yb$^{3+}$ ion instead of the Yb-CS hydrogel to detect variations in the apoptosis level in response to different concentrations of Yb$^{3+}$. We seeded B-16 and L929 cells into an E-plate with Yb$^{3+}$ at different concentrations (0, 0.01, 0.1, 0.5, 1.0, and 1.5 mM) (Figure 6a). The cell index was analyzed using an RTCA DP analyzer. The results showed that the cell index of B-16 cells decreased in a dose-dependent manner, whereas that of L929 cells only decreased at concentrations above 1.0 mmol/L. The data shown in Figure 6a were plotted as a relative bar graph showing certain timepoints (1, 2, 3, 4, and 5 days) and indicated that compared with that of L929 cells, the relative cell index of B-16 cells decreased to a greater degree in the high-dose groups (1.0 and 1.5 mmol/L) than in the other groups (Figure 6b). L929 cells grew slowly at 5 days after treatment with 1.0 mM Yb$^{3+}$. These results implied that more B-16 cells may undergo apoptosis under Yb$^{3+}$ treatment than L929 cells.

To more precisely analyze apoptosis, flow cytometry and western blotting of typical apoptosis proteins were performed. In the FCM-based assays, the total percentage of dead cells was 19.8±3.41% (4.96±1.62% early apoptotic cells, 9.24±2.58% late apoptotic cells and 5.43±1.14% dead or necrotic cells) and 8.63±3.79% (5.98±3.79% early apoptotic cells, 2.66±0.57% late apoptotic cells and 0.45±0.24% dead or necrotic cells) for B-16 cells and L929 cells treated with 1.0 mM Yb$^{3+}$ at 24 h, respectively (Figure 6c). At 24 h after B-16 and L929 cells were treated with 1.5 mmol/L Yb$^{3+}$, the total percentage of dead cells was 31.47±2.52% (4.56±1.46% early apoptotic cells, 5.16±2.08% late apoptotic cells and 21.74±0.9% dead or necrotic cells) and 11.53±3.97% (7.99±3.92% early apoptotic cells, 3.22±0.15% late apoptotic cells and 0.31±0.07% dead or necrotic cells), respectively (Table S1). These results indicate that Yb$^{3+}$ induces more apoptosis in B-16 cells than in L929 cells.

To determine whether cells treated with Yb$^{3+}$ underwent apoptosis, we detected the cleavage of typical apoptosis proteins, PARP and caspase 3 (Table S2). The results showed that the expression levels of cleaved-PARP and cleaved-caspase 3 (the active forms of PARP and caspase 3, respectively) greatly increased after Yb$^{3+}$ treatment (Figure 6d). However, the expression levels of pro-PARP and pro-caspase 3 (the inactive forms of PARP and caspase 3, respectively) increased (Figure 6d).

3.7 Yb$^{3+}$ ions trigger the anoikis of B-16 cells in a focal adhesion kinase (FAK)-dependent manner

After inducing the apoptosis of B-16 cells by Yb$^{3+}$, we observed morphological changes in B-16 cells. To visualize these changes, microfilaments (mainly F-actin) were stained with FITC-phalloidin. The results obviously showed that B-16 cell morphology varied from ovoid to slender shapes, whereas nearly no morphological changes were observed in L929 cells after treatment.
Yb$^{3+}$-containing chitosan hydrogels induce B-16 melanoma cell anoikis via a Fak-dependent pathway

Figure 5: The Yb$^{3+}$-containing hydrogel inhibits melanoma progression in mouse models. (a) The procedure of the mouse experiment. (b-e) Melanoma cells were injected into both sides of the abdomen in subcutaneous tissues in SD mice. The xenografts were observed approximately 10 days later (b). Both sides of the tumor were incompletely resected (c), and the wounds were covered with an Yb$^{3+}$-containing hydrogel or a blank hydrogel (d). The wounds were sutured, and the open area remained covered with gauze and a plastic protector (e). The gauze and plastic protector were removed, and the wounds covered with the Yb$^{3+}$-containing hydrogel (f) and the blank hydrogel (g) were analyzed after 2 weeks to detect the recurrence of melanoma. IHC of ki-67 was carried out on the skin tissues, including the implanted hydrogel (h-j) and relapsed melanoma tissue (k-m)
Figure 6: Yb$^{3+}$ induces higher apoptosis rates in B-16 cells than in L929 cells. (a) RTCA assay results of B-16 and L929 cells in medium containing Yb$^{3+}$ at different concentrations. Cells were first cultured in regular medium for 24 h (red arrow) and then treated with the Yb$^{3+}$ ion. (b) Relative cell growth of B-16 and L929 cells at different timepoints (1, 2, 3, 4, and 5 days) obtained from the RTCA data. (c) Flow cytometry results of B-16 and L929 cells treated with medium containing different concentrations of Yb$^{3+}$ for 24 h. (d) Western blot of apoptosis marker proteins (caspase3 and PARP and their cleaved forms) in B-16 and L929 cells treated with medium containing different concentrations of Yb$^{3+}$ for 24 h. Relative expression of Cleaved-PARP and Cleaved Caspase3 in B-16 and L929 cells based on the western blot results. *p<0.05, **p<0.01
The presence of filament structures indicated the shrinkage of entire B-16 cells, which may then induce cell detachment (Figure 7a). Therefore, we hypothesized that Yb\(^{3+}\)-containing hydrogels induce cell detachment-dependent apoptosis-anoikis. To verify this hypothesis, cell adhesion assays of B-16 and L929 cells were performed under standard conditions by counting cells that were seeded into hydrogels containing different concentrations (0, 0.01, 0.1, and 1.0 mM) of Yb\(^{3+}\) for 2 h. The results showed that the numbers of B-16 cells decreased with increasing concentrations of Yb\(^{3+}\) (Figure 7b). For an accurate analysis, RTCA assays were employed to show the inhibition of cell adhesion by Yb\(^{3+}\). The results indicated that B-16 cell adhesion was inhibited after treatment with 0.5, 1.0, and 1.5 mM Yb\(^{3+}\) (Figure 7c). The relative cell adhesion analysis showed that B-16 cells treated with 0.5, 1.0, and 1.5 mM Yb\(^{3+}\) had significantly lower cell adhesion at 2 h. Furthermore, L929 cells only showed decreased cell adhesion after treatment with 1.5 mM Yb\(^{3+}\) (P<0.05).

To further confirm these results, we determined the expression of marker proteins related to anoikis, including FAK, AKT and their phosphorylated forms. A high phosphorylation level of these proteins indicates high cell adhesion. Our results revealed that the expression levels of p-FAK and P-AKT were apparently decreased after B-16 cells were treated with higher concentrations of Yb\(^{3+}\) (Figure 7d-e), whereas the expression levels of p-FAK and P-AKT were only slightly decreased in L929 cells (Figure 7d). The total expression levels of FAK and AKT in each group of B-16 and L929 cells remained nearly unchanged (Table S3).

4 Discussion

Melanoma is a lethal dermal-derived tumor with high relapse potential. However, a postoperative standard adjuvant therapy, which could prevent the relapse of melanoma, has not been developed. In this study, we developed an Yb\(^{3+}\)-containing chitosan hydrogel to inhibit the growth of melanoma (Figure 8). Our results clearly showed that chitosan hydrogel containing a high concentration of Yb\(^{3+}\) (0.5~1.5 mM) inhibited the proliferation of B-16 mouse melanoma cells and L929 normal mouse skin fibroblast cells and induced apoptosis. We also demonstrated that Yb\(^{3+}\) is the main factor in the hydrogel that induces apoptosis. Interestingly, upon detecting the effect of Yb\(^{3+}\) ions in inducing apoptosis, we found that under certain conditions (Yb\(^{3+}\) ion concentrations of 0.5 and 1.0 mM), the B16 cell apoptosis phenomenon is more obvious than that of L929 cells, which may mean that B-16 cells are more sensitive to Yb\(^{3+}\) than L929 cells. Furthermore, higher expression levels of cleaved-PARP and cleaved-caspase3 were detected in B-16 cells than in L929 cells. These results were also consistent with the results from the animal experiments. In vivo, Yb\(^{3+}\)-containing hydrogels inhibited the growth of melanoma but had no harmful influence on skin union and peripheral normal tissue damage. Moreover, we also showed that cell death induced by Yb\(^{3+}\) ions was anoikis, which was verified by cell adhesion assays and FAK phosphorylation levels of B-16 and L929 cells after treatment with either Yb\(^{3+}\)-containing chitosan hydrogels or Yb\(^{3+}\) ions alone. In addition, the morphological changes and cytoskeletal network rearrangement of B-16 and L929 cells treated with Yb\(^{3+}\) also indicated that Yb\(^{3+}\)-containing hydrogels induced cell anoikis.

Anoikis is a special form of apoptosis characterized by anchorage loss between cells and their surrounding extracellular matrix (ECM) [26]. Similar to classic apoptosis, anoikis could be triggered from either intrinsic pathways, due to the unsteadiness of mitochondria, or extrinsic pathways triggered by cell surface membrane protein kinases [27]. FAK, which is a nonreceptor protein tyrosine kinase, is indispensable in cell-substratum adhesions named focal adhesion complexes. Therefore, FAK is important in the maintenance of normal cell survival. Disruption of FAK signaling results in anoikis of anchorage-dependent cells, such as endothelial and epithelial cells. Most importantly, FAK is overexpressed in a variety of invasive human tumors and is believed to contribute to malignancies [29]. Moreover, tumor cells with high metastatic potential are inclined to escape from anoikis during hematogenous metastasis and invade other organs. Therefore, the promotion of anoikis by interfering with FAK activity is a promising strategy for the development of anticancer drugs. In 2009, Su et al. [30] reported for the first time that lanthanum citrate (LaCit) at concentrations of 0.001-0.1 mmol/L induces the anoikis of HeLa cells after 48 h. They also showed that the intrinsic caspase pathway is involved in the anoikis induced by LaCit and reorganization of the actin cytoskeleton, which is consistent with our results. Until now, the study conducted by Su et al. [30], was the only study of a lanthanide compound inducing tumor cell anoikis. Therefore, our study showed that Yb\(^{3+}\) induced melanoma cell anoikis and validated the hypothesis that lanthanide compounds induce cell anoikis. However, whether anoikis is the only pathway that induces apoptosis still needs to be investigated.

As mentioned above, the results from this study showed that a Yb\(^{3+}\)-containing chitosan hydrogel is capable of inducing melanoma cell anoikis, and this is the first study to show that Yb\(^{3+}\) induces the anoikis of tumor...
Figure 7: Yb\(^{3+}\) induced the anoikis of B-16 cells by FAK signaling. (a) FITC-phalloidin staining for F-actin in B-16 and L929 cells on hydrogels containing different concentrations of Yb\(^{3+}\). (b) Cell adhesion assays of B-16 and L929 cells on the same hydrogels using SYBR I. (c) RTCA assays for detecting cell adhesion and spreading of B-16 and L929 cells cultured in medium containing different concentrations of Yb\(^{3+}\) within 6 h. The relative cell adhesion rates are shown for the 2 h timepoint (*p<0.05). (d) Western blot of anoikis marker proteins (FAK, Akt and their phosphorylated forms) in B-16 and L929 cells treated with medium containing different concentrations of Yb\(^{3+}\) at 24 h. (e) Relative expression of P-Akt and P-Fak in B-16 and L929 cells based on the results of western blot analysis (*p<0.05, **p<0.01)
cells. Therefore, the novel Yb\(^{3+}\)-containing chitosan hydrogel that we developed not only can inhibit the relapse of melanoma cells but also has no harmful influence on skin union and peripheral normal tissue damage, which provides a foundation for applying yttrium-containing compounds to anti-recurrence treatments in melanoma patients.

5 Conclusions

In summary, we reported that an Yb-CS hydrogel induces tumor cell death but has less impact on normal dermal cells, and we also revealed that Yb\(^{3+}\) induces the anoikis of tumor cells through a Fak-dependent pathway. Therefore, the Yb-CS hydrogel could be a suitable and effective strategy for treating melanoma.

Acknowledgement: This study was supported by the Shanghai Jiao tong University Medical and Industry cross fund (Award Number: YG2017MS21) and the National Natural Science Foundation of China (Award Number: No.81501939).

Ethical approval: The conducted research was performed in accordance with relevant regulations and was approved by the Shanghai Jiao Tong University Affiliated Sixth People’s Hospital Ethical Board.

Conflict of Interests: The authors have no conflict of interest regarding the publication of this paper.

References

[1] Corrie P., Hategan M., Fife K., Parkinson C., Management of melanoma, Br. Med. Bull., 2014, 1111, 149-162.
[2] Gandolfi G., Dallaglio K., Longo C., Moscarella E., Lallas A., Alfano R. et al., Contemporary and potential future molecular diagnosis of melanoma, Expert Rev. Mol. Diagn., 2016, 169, 975-985.
[3] Wang Y., Tu Y., Lu J., Tao J., Li Y., c-FLIPp43 induces activation of the nuclear factorkappaB signaling pathway in a dose-dependent manner in the A375 melanoma cell line, Mol. Med. Rep., 2014, 103, 1438-1442.
[4] Menzies A.M., Long G.V., Recent Developments in Melanoma Therapy, JAMA Oncol., 2016, 210, 1259-1260.
[5] Friedman E.B., Shang S., de Miera E.V., Fog J.I., Teilm M.W., Ma M.W. et al., Serum microRNAs as biomarkers for recurrence in melanoma, J. Transl. Med., 2012, 10, 155.
[6] Dabrowski E., Dippel E., Systemic treatment of distant metastatic malignant melanoma, Radioloege, 2015, 552, 99-100, 102-104.
[7] Dzwierzynski W.W., Managing malignant melanoma, Plast. Reconstr. Surg., 2013, 1323, 446e-460e.
[8] Bedikian A.Y., Metastatic uveal melanoma therapy: current options, Int Ophthalmol. Clin., 2006, 461, 151-166.
[9] Das Thakur M., Salangsang F., Landman A.S., Sellers W.R., Pryer N.K., Levesque M.P. et al., Modelling vemurafenib resistance in
melanoma reveals a strategy to forestall drug resistance, Nature, 2013, 4947436, 251-255.

[10] Yu L., Xiong J., Guo L., Miao L., Liu S., Guo F., The effects of lanthanum chloride on proliferation and apoptosis of cervical cancer cells: involvement of let-7a and miR-34a microRNAs, Biometals, 2015, 285, 879-890.

[11] Wang F., Zhu Y., Fang S., Li S., Liu S., Lanthanum chloride enhances cisplatin-induced apoptosis in ovarian cancer cells, Cell Mol. Biol. (Noisy-le-grand), 2016, 627, 1-5.

[12] Shi P., Huang Z., Proteomic detection of changes in protein synthesis induced by lanthanum in BGC-823 human gastric cancer cells, Biometals, 2005, 181, 89-95.

[13] Tsai Y.F., Huang C.W., Chiang J.H., Tsai F.J., Hsu Y.M., Lu C.C. et al., Gadolinium chloride elicits apoptosis in human osteosarcoma U-2 OS cells through extrinsic signaling, intrinsic pathway and endoplasmic reticulum stress, Oncol. Rep., 2016, 366, 3421-3426.

[14] Lin C.M., Ma J.M., Zhang L., Hao Z.Y., Zhou J., Zhou Z.Y. et al., Inhibition of Transient Receptor Potential Melastain 7 Enhances Apoptosis Induced by TRAIL in PC-3 cells, Asian Pac. J. Cancer Prev., 2015, 1610, 4469-4475.

[15] Chen X., Xie W., Gu P., Cai Q., Wang B., Xie Y. et al., Upregulated WDR5 promotes proliferation, self-renewal and chemoresistance in bladder cancer via mediating H3K4 trimethylation, Sci. Rep., 2015, 5, 8293.

[16] Ye L., Shi Z., Liu H., Yang X., Wang K., GdCl3 induced Hep G2 cell death through mitochondrial and external death pathways without significant elevation of ROS generation, Biol. Trace Elem. Res., 2013, 1511, 148-155.

[17] Frisch S.M., Schaller M., Cieply B., Mechanisms that link the oncogenic epithelial–mesenchymal transition to suppression of anoikis, J. Cell Sci., 2013, 1261, 21-29.

[18] Alanko J., Ivaska J., Endosomes: emerging platforms for integrin-mediated FAK signalling, Trends Cell Biol., 2016, 266, 391-398.

[19] Golubovskaya V.M., Conway-Dorsey K., Edmiston S.N., Tse C.-K., Lark A.A., Livasy C.A., et al., FAK overexpression and p53 mutations are highly correlated in human breast cancer, Int. J. Cancer, 2009, 1257, 1735-1738.

[20] Ahmed A.A.A., Talib Z.A., Hussein M.Z., Synthesis and optimization of electric conductivity and thermal diffusivity of zinc-aluminum hydroxide (Zn–Al–NO₃–LDH) prepared at different pH values, Mater. Today Proc., 2016, 32, 130-144.

[21] Paoli P., Giannoni E., Chiarugi P., Anoikis molecular pathways and its role in cancer progression, Biochim. Biophys. Acta. Mol. Cell Res., 2013, 183312, 3481-3498.

[22] Frisch S.M., Schaller M., Cieply B., Mechanisms that link the oncogenic epithelial–mesenchymal transition to suppression of anoikis, J. Cell Sci., 2013, 1261, 21-29.

[23] Golubovskaya V.M., Conway-Dorsey K., Edmiston S.N., Tse C.-K., Lark A.A., Livasy C.A., et al., FAK overexpression and p53 mutations are highly correlated in human breast cancer, Int. J. Cancer, 2009, 1257, 1735-1738.

[24] Su X., Zheng X., Ni J., Lanthanum citrate induces anoikis of Hela cells, Cancer Lett., 2009, 2852, 200-209.
**Supplementary Materials**

**Table S1:** The data of FCM-based apoptosis results. B-16 and L929 cells were treated with Yb3+ at 0, 0.1, 0.5, 1.0, 1.5mmol/L. (Mean±SD)

|       | B16-ctrl | B16-0.1mM | B16-0.5mM | B16-1.0mM | B16-1.5mM |
|-------|----------|-----------|-----------|-----------|-----------|
| Q1    | 2.27±0.44| 1.97±0.34 | 4.13±0.32 | 5.43±1.14 | 21.74±0.9 |
| Q2    | 91.51±1.46| 90.4±1.55  | 88.75±1.5  | 80.2±3.41 | 68.53±2.52 |
| Q3    | 2.82±1.08 | 3.54±1.02  | 2.91±0.91  | 4.96±1.62 | 4.56±1.46 |
| Q4    | 3.4±0.73  | 4.1±0.86   | 4.22±0.9   | 9.24±2.58 | 5.16±2.08 |
| Q2+Q3+Q4 | 8.49±1.46 | 9.6±1.55   | 11.25±1.5  | 19.8±3.41 | 31.47±2.52 |

|       | L929-ctrl | L929-0.1mM | L929-0.5mM | L929-1.0mM | L929-1.5mM |
|-------|-----------|-----------|-----------|-----------|-----------|
| Q1    | 1.25±0.46 | 1.06±0.05 | 0.37±0.11 | 0.45±0.24 | 0.31±0.07 |
| Q2    | 95.29±1.82| 96.25±1.11| 89.48±5.73| 90.92±3.47| 88.47±3.97|
| Q3    | 0.78±0.62 | 0.64±0.31 | 7.15±4.97 | 5.98±3.79 | 7.99±3.92 |
| Q4    | 2.68±0.96 | 2.06±0.94 | 2.66±0.63 | 2.66±0.57 | 3.22±0.15 |
| Q2+Q3+Q4 | 4.71±1.82 | 3.75±1.11 | 10.52±5.73| 9.08±3.47 | 11.53±3.97|

Q1: Upper left quadrant; Q2: left lower quadrant; Q3: right upper quadrant; Q4: right lower quadrant.

**Table S2:** Relative protein expression of PARP, Cleaved-PARP, Caspase3, Cleaved-Caspase3 from Western-blot data (Mean±SD)

|       | PARP      | Cleaved-PARP | Caspase3 | Cleaved-Caspase3 |
|-------|-----------|--------------|----------|------------------|
| B16-Ctrl | 0.916±0.172| 0.288±0.108 | 1.088±0.046| 0.537±0.017    |
| B16-0.01 | 0.842±0.142| 0.347±0.099 | 0.866±0.029| 0.549±0.01    |
| B16-0.1  | 0.779±0.134| 0.356±0.034 | 0.723±0.013| 0.590±0.015   |
| B16-0.5  | 0.08±0.022 | 0.751±0.077 | 0.69±0.035 | 0.382±0.042   |
| B16-1.0  | 0.091±0.019| 1.09±0.052  | 0.863±0.047| 1.004±0.049   |
| B16-1.5  | 0.187±0.032| 1.804±0.092 | 1.138±0.008| 0.930±0.126   |
| L929-Ctrl| 0.716±0.067| 0.187±0.037 | 0.738±0.01 | 0.14±0.01     |
| L929-0.01| 0.746±0.073| 0.273±0.042 | 0.638±0.018| 0.266±0.032   |
| L929-0.1 | 0.885±0.049| 0.33±0.037  | 0.711±0.03 | 0.326±0.045   |
| L929-0.5 | 0.07±0.018 | 0.613±0.006 | 0.864±0.061| 0.25±0.041    |
| L929-1.0 | 0.133±0.015| 1.07±0.034  | 0.71±0.008 | 0.539±0.07    |
| L929-1.5 | 0.183±0.018| 0.566±0.051 | 0.564±0.012| 0.844±0.016   |
Table S3: Relative protein expression of P-Akt, Akt, P-Fak, Fak from Western-blot data (Mean±SD)

|        | P-Akt | Akt   | P-Fak | Fak   |
|--------|-------|-------|-------|-------|
| B16-Ctrl | 1.244±0.097 | 0.657±0.049 | 0.634±0.07 | 0.282±0.022 |
| B16-0.01 | 0.813±0.119 | 0.497±0.016 | 0.54±0.045 | 0.2±0.018   |
| B16-0.1  | 0.535±0.075 | 0.462±0.03  | 0.38±0.032 | 0.212±0.016 |
| B16-0.5  | 0.241±0.054 | 0.355±0.025 | 0.36±0.039 | 0.209±0.009 |
| B16-1.0  | 0.254±0.049 | 0.346±0.018 | 0.258±0.02 | 0.177±0.013 |
| B16-1.5  | 0.212±0.041 | 0.428±0.02  | 0.272±0.027| 0.21±0.018  |
| L929-Ctrl| 0.936±0.129 | 0.401±0.011 | 0.49±0.044 | 0.327±0.022 |
| L929-0.01| 0.795±0.091 | 0.452±0.003 | 0.484±0.039| 0.284±0.017 |
| L929-0.1 | 0.648±0.105 | 0.452±0.011 | 0.42±0.028 | 0.255±0.025 |
| L929-0.5 | 0.544±0.086 | 0.435±0.02  | 0.474±0.055| 0.258±0.03  |
| L929-1.0 | 0.504±0.082 | 0.48±0.019  | 0.415±0.029| 0.202±0.022 |
| L929-1.5 | 0.515±0.076 | 0.404±0.029 | 0.436±0.03 | 0.184±0.022 |